In the print publication the data in Table 2, has been incorrectly published.
Page 95, Table 2, final row, second column: the mean Advanced treatment annual cost which
previously read 83,249
should read 8324,
Institute for Medical Technology Assessment (iMTA)

Ansaripour, A., Uyl-de Groot, C., & Redekop, K. (2018). Erratum to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy (PharmacoEconomics, (2018), 36, 1, (91-103), 10.1007/s40273-017-0557-6). PharmacoEconomics, 36(4). doi:10.1007/s40273-018-0634-5